ms LAUREN FULLER

Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013-NASPER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528)

Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013 - NAPSER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528).

Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013- NASPER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528).

Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S557/HR1024 legislation that would expand Medicare Part D Medication Therapy Management benefit to one or more chronic diseases as defined in the legislation; Controlled substances -- advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled subances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the useof preferred networks to improve pharmacy performance measures; CMS Proposed Rule/Medicare Part D, including HR 4160

Opposition to legislation that would amend Medicare Part D to require health plans to include any willing pharmacy in its network if the pharmacy is located in a medically underserved area of among a medically underserved population - H.R. 4577. Opposition to limiting the ability of health plans to include preferred networks in their pharmacy network.

Opposition to legislation that would amend Medicare Part D to require health plans to include any willing pharmacy in its network if the pharmacy is located in a medically underserved area or among a medically underserved population - HR 4577. Opposition to limiting the ability of health plans to include preferred networks in their pharmacy network.

Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013-NASPER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528)

Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013 - NAPSER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528).

Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013- NASPER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528).

Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S557/HR 1024 legislation that would expand Medicare Part D Medication Therapy Management benefit to one or more chronic diseases as defined in the legislation; Controlled substances--advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program.

Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S557/HR1024 legislation that would expand Medicare Part D Medication Therapy Management benefit to one or more chronic diseases as defined in the legislation; Controlled substances--advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program.

Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S557/HR1024 legislation that would expand Medicare Part D Medication Therapy Management benefit to one or more chronic diseases as defined in the legislation; Controlled substances -- advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled subances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the useof preferred networks to improve pharmacy performance measures; CMS Proposed Rule/Medicare Part D, including HR 4160

S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors -- Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D -- S 557/HR 1024 -- legislation would expand Medication Therapy Management benefit to one or morechronic diseases as defined in the legislation

S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S557/HR 1024 - legislation would expand Medicare Part D Medication Therapy Management benefit to one or more chronic disease as defined in the legislation; Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S77, S117/HR 1102 - legislation would require HHS Secretary to negotiate prescription drugprices on behalf of Medicare Part D plan sponsors; Controlled substances - advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the use of preferred networks to improve pharmacy performance measures; Medicare Accountable Care Organizations (ACO) - supporting the inclusion on pharmacists as providers in ACOs as an amendment to the Medicare sustainable growth rate

S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require the Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors - Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D.

S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors -- Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D -- S 557/HR 1024 -- legislation would expand Medication Therapy Management benefit to one or morechronic diseases as defined in the legislation

S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S557/HR 1024 - legislation would expand Medicare Part D Medication Therapy Management benefit to one or more chronic disease as defined in the legislation; Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S77, S117/HR 1102 - legislation would require HHS Secretary to negotiate prescription drugprices on behalf of Medicare Part D plan sponsors; Controlled substances - advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the use of preferred networks to improve pharmacy performance measures; Medicare Accountable Care Organizations (ACO) - supporting the inclusion on pharmacists as providers in ACOs as an amendment to the Medicare sustainable growth rate

S 77/S 117/HR 1102 - legislation that would require or allow the federal government to negotiate prescription drug prices for Medicare Part D plan sponsors; Proposals to expand Medicaid "best price" rebates to dual eligibles in Medicare Part D; proposal repeal requirement that Part D plan sponsors cover all or substantially all drugs in therapeutic classes of concern; worked on proposed legislative language, which included consultation with Senate committee staff and discussions with personal staff of Houseand Senate members, that would amend the current prompt payment rules in Part D in the interest of preventing fraud.

S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S557/HR 1024 - legislation would expand Medicare Part D Medication Therapy Management benefit to one or more chronic disease as defined in the legislation; Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S77, S117/HR 1102 - legislation would require HHS Secretary to negotiate prescription drugprices on behalf of Medicare Part D plan sponsors; Controlled substances - advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the use of preferred networks to improve pharmacy performance measures; Medicare Accountable Care Organizations (ACO) - supporting the inclusion on pharmacists as providers in ACOs as an amendment to the Medicare sustainable growth rate

S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors -- Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D -- S 557/HR 1024 -- legislation would expand Medication Therapy Management benefit to one or morechronic diseases as defined in the legislation

S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require the Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors - Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D.

S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs -- HR 2186 requires registration of manufacturers that compound and requires Secretary to develop list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy -- S 957 legislation establishes uniform national policy for the drug supply chain -- HR 1919 legislation provides enhanced securityin the drug distribution chain

S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs HR 2186 - requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy. S 957 legislation establishes a uniform national policy for the drug supply chain HR 1919 legislation provides enhanced securityin the drug distribution chain

S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs; HR 2186 requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded; S 957/HR 1919 legislation that establishes uniform national policy to protect the safety of the drug supply chain; biosimilar naming - supporting Congressional action to seek FDA decision on biosimilar naming

S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs; HR 2186 requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded; S 957/HR 1919 legislation that establishes uniform national policy to protect the safety of the drug supply chain; biosimilar naming - supporting Congressional action to seek FDA decision on biosimilar naming

S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs -- HR 2186 requires registration of manufacturers that compound and requires Secretary to develop list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy -- S 957 legislation establishes uniform national policy for the drug supply chain -- HR 1919 legislation provides enhanced securityin the drug distribution chain

S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs HR 2186 - requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy. S 957 legislation establishes a uniform national policy for the drug supply chain HR 1919 legislation provides enhanced securityin the drug distribution chain

S 77/S 117/HR 1102 - legislation that would require or allow the federal government to negotiate prescription drug prices for Medicare Part D plan sponsors; Proposals to expand Medicaid "best price" rebates to dual eligibles in Medicare Part D; proposal repeal requirement that Part D plan sponsors cover all or substantially all drugs in therapeutic classes of concern; worked on proposed legislative language, which included consultation with Senate committee staff and discussions with personal staff of Houseand Senate members, that would amend the current prompt payment rules in Part D in the interest of preventing fraud.

S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S557/HR 1024 - legislation would expand Medicare Part D Medication Therapy Management benefit to one or more chronic disease as defined in the legislation; Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S77, S117/HR 1102 - legislation would require HHS Secretary to negotiate prescription drugprices on behalf of Medicare Part D plan sponsors; Controlled substances - advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the use of preferred networks to improve pharmacy performance measures; Medicare Accountable Care Organizations (ACO) - supporting the inclusion on pharmacists as providers in ACOs as an amendment to the Medicare sustainable growth rate

S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors -- Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D -- S 557/HR 1024 -- legislation would expand Medication Therapy Management benefit to one or morechronic diseases as defined in the legislation

S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require the Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors - Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D.

S 214 - legislation that would presume illegal patent settlement agreements between brand-name and generic manufacturers in which the brand-name manufacturer compensates the generic manufacturer to delay market entry of a generic drug; proposal to shorten the length of data exclusivity for reference biologic products from 12 years to 7 years; proposals to allow importation of prescription drugs from foreign countries

S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S557/HR 1024 - legislation would expand Medicare Part D Medication Therapy Management benefit to one or more chronic disease as defined in the legislation; Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S77, S117/HR 1102 - legislation would require HHS Secretary to negotiate prescription drugprices on behalf of Medicare Part D plan sponsors; Controlled substances - advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the use of preferred networks to improve pharmacy performance measures; Medicare Accountable Care Organizations (ACO) - supporting the inclusion on pharmacists as providers in ACOs as an amendment to the Medicare sustainable growth rate

S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors -- Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D -- S 557/HR 1024 -- legislation would expand Medication Therapy Management benefit to one or morechronic diseases as defined in the legislation

S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S557/HR 1024 - legislation would expand Medicare Part D Medication Therapy Management benefit to one or more chronic disease as defined in the legislation; Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S77, S117/HR 1102 - legislation would require HHS Secretary to negotiate prescription drugprices on behalf of Medicare Part D plan sponsors; Controlled substances - advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the use of preferred networks to improve pharmacy performance measures; Medicare Accountable Care Organizations (ACO) - supporting the inclusion on pharmacists as providers in ACOs as an amendment to the Medicare sustainable growth rate

S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require the Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors - Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D.

S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors -- Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D -- S 557/HR 1024 -- legislation would expand Medication Therapy Management benefit to one or morechronic diseases as defined in the legislation

S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors -- Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D -- S 557/HR 1024 -- legislation would expand Medication Therapy Management benefit to one or morechronic diseases as defined in the legislation

S 77/S 117/HR 1102 - legislation that would require or allow the federal government to negotiate prescription drug prices for Medicare Part D plan sponsors; Proposals to expand Medicaid "best price" rebates to dual eligibles in Medicare Part D; proposal repeal requirement that Part D plan sponsors cover all or substantially all drugs in therapeutic classes of concern; worked on proposed legislative language, which included consultation with Senate committee staff and discussions with personal staff of Houseand Senate members, that would amend the current prompt payment rules in Part D in the interest of preventing fraud.

S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S557/HR 1024 - legislation would expand Medicare Part D Medication Therapy Management benefit to one or more chronic disease as defined in the legislation; Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D; S77, S117/HR 1102 - legislation would require HHS Secretary to negotiate prescription drugprices on behalf of Medicare Part D plan sponsors; Controlled substances - advocating that Congress consider legislation to address the inappropriate utilization, diversion and abuse of certain controlled substances in the Medicare Part D program; Preferred networks - advocating that CMS recognize the importance of the use of preferred networks to improve pharmacy performance measures; Medicare Accountable Care Organizations (ACO) - supporting the inclusion on pharmacists as providers in ACOs as an amendment to the Medicare sustainable growth rate

S 740/HR 1588 - legislation would require manufacturers to pay Medicaid "best price" rebates for prescription drugs purchased by dual eligibles covered under Medicare Part D; S 77/S 177/HR 1102 - legislation would require the Secretary of HHS to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors - Academy of Managed Care Pharmacy draft bill concerning fraud and Medicare Part D.

S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs -- HR 2186 requires registration of manufacturers that compound and requires Secretary to develop list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy -- S 957 legislation establishes uniform national policy for the drug supply chain -- HR 1919 legislation provides enhanced securityin the drug distribution chain

S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs HR 2186 - requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy. S 957 legislation establishes a uniform national policy for the drug supply chain HR 1919 legislation provides enhanced securityin the drug distribution chain

S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs; HR 2186 requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded; S 957/HR 1919 legislation that establishes uniform national policy to protect the safety of the drug supply chain; biosimilar naming - supporting Congressional action to seek FDA decision on biosimilar naming

S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs; HR 2186 requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded; S 957/HR 1919 legislation that establishes uniform national policy to protect the safety of the drug supply chain; biosimilar naming - supporting Congressional action to seek FDA decision on biosimilar naming

S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs HR 2186 - requires registration of manufacturers that compound and requires Secretary to develop a list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy. S 957 legislation establishes a uniform national policy for the drug supply chain HR 1919 legislation provides enhanced securityin the drug distribution chain

S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs -- HR 2186 requires registration of manufacturers that compound and requires Secretary to develop list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy -- S 957 legislation establishes uniform national policy for the drug supply chain -- HR 1919 legislation provides enhanced securityin the drug distribution chain

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts. HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare Part D plan sponsors. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; HR 6392 - legislation that would allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891/S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31/S 44/HR 2248/HR 6392 - legislation taht would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999/S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plans to offer "off-label" coverage HR 2190/S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" revates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Part D plan sponsors; worked on proposed legislative language, which included consultation with Senate committee staff and discussions with personal staff of House and Senate members, that would amend the current prompt payment rules in Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufaturer agrees to delay entry into the market in exhange for compensation from the manufacturer of the innovator product HR 1483 & HR 3988 - would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program HR 4209 - legislation that would require group and individual health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payment/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate terms and conditions with health plans and pharamcy benefit managers.

HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.

HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate terms and conditions with health plans and pharamcy benefit managers.

HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate terms and conditions with health plans and pharamcy benefit managers.

HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate terms and conditions with health plans and pharamcy benefit managers.

HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufaturer agrees to delay entry into the market in exhange for compensation from the manufacturer of the innovator product HR 1483 & HR 3988 - would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program HR 4209 - legislation that would require group and individual health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payment/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medication within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payments/co-insurance rate for non-preferred brand drugs; HR 1971/S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans; HR 6584 - legislation that would impose federal requirements on compounding pharmacies

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 5651 and S 3187 - reauthorization of the prescription drug user fee act; S 296 and HR 2245 - legislation that would address shortages of prescription drugs; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; HR 6392 - legislation that would allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891/S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31/S 44/HR 2248/HR 6392 - legislation taht would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999/S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plans to offer "off-label" coverage HR 2190/S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" revates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Part D plan sponsors; worked on proposed legislative language, which included consultation with Senate committee staff and discussions with personal staff of House and Senate members, that would amend the current prompt payment rules in Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts. HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare Part D plan sponsors. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufaturer agrees to delay entry into the market in exhange for compensation from the manufacturer of the innovator product HR 1483 & HR 3988 - would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program HR 4209 - legislation that would require group and individual health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payment/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 5651 and S 3187 - reauthorization of the prescription drug user fee act; S 296 and HR 2245 - legislation that would address shortages of prescription drugs; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

HR 891/S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31/S 44/HR 2248/HR 6392 - legislation taht would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999/S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plans to offer "off-label" coverage HR 2190/S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" revates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Part D plan sponsors; worked on proposed legislative language, which included consultation with Senate committee staff and discussions with personal staff of House and Senate members, that would amend the current prompt payment rules in Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; HR 6392 - legislation that would allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts. HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare Part D plan sponsors. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufaturer agrees to delay entry into the market in exhange for compensation from the manufacturer of the innovator product HR 1483 & HR 3988 - would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program HR 4209 - legislation that would require group and individual health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payment/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medication within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payments/co-insurance rate for non-preferred brand drugs; HR 1971/S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans; HR 6584 - legislation that would impose federal requirements on compounding pharmacies

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 5651 and S 3187 - reauthorization of the prescription drug user fee act; S 296 and HR 2245 - legislation that would address shortages of prescription drugs; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; HR 6392 - legislation that would allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts. HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare Part D plan sponsors. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891/S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31/S 44/HR 2248/HR 6392 - legislation taht would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999/S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plans to offer "off-label" coverage HR 2190/S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" revates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Part D plan sponsors; worked on proposed legislative language, which included consultation with Senate committee staff and discussions with personal staff of House and Senate members, that would amend the current prompt payment rules in Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts. HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare Part D plan sponsors. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; HR 6392 - legislation that would allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufaturer agrees to delay entry into the market in exhange for compensation from the manufacturer of the innovator product HR 1483 & HR 3988 - would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program HR 4209 - legislation that would require group and individual health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payment/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufaturer agrees to delay entry into the market in exhange for compensation from the manufacturer of the innovator product HR 1483 & HR 3988 - would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program HR 4209 - legislation that would require group and individual health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payment/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 5651 and S 3187 - reauthorization of the prescription drug user fee act; S 296 and HR 2245 - legislation that would address shortages of prescription drugs; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 2746 - legislation that would require cost-sharing parity between all cancer medication within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payments/co-insurance rate for non-preferred brand drugs; HR 1971/S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans; HR 6584 - legislation that would impose federal requirements on compounding pharmacies

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891/S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31/S 44/HR 2248/HR 6392 - legislation taht would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999/S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plans to offer "off-label" coverage HR 2190/S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" revates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Part D plan sponsors; worked on proposed legislative language, which included consultation with Senate committee staff and discussions with personal staff of House and Senate members, that would amend the current prompt payment rules in Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage of medications HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts. HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare Part D plan sponsors. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

HR 891 and S 274 - legislation that would expand the existing medication therapy management program in Medicare Part D; S 31 and S 44 and HR 2248 and HR 3638 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government; HR 1055 - legislation that would allow Part D plan sponsors to offer "off-label" coverage HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D; HR 3613 - legislation that would require Medicare Part D plans to establish an exceptions process for patient cost-sharing amounts; HR 4215 - legislation that would establish audit requirements and other transparency requirements for Medicare part D plan sponsors; HR 6392 - legislation that would allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors; Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.

S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product; HR 5651 and S 3187 - reauthorization of the prescription drug user fee act; S 296 and HR 2245 - legislation that would address shortages of prescription drugs; HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA; HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program; HR 4209 - legislation that would require individual and group health insurance policies covered under ERISA and which use a formulary for prescription drug coverage to charge the same co-payments/co-insurance rate for specialty drugs as the co-payment/co-insurance rate for non-preferred brand drugs. HR 1971 and S 1058 - legislation that would impose transparency and audit requirements for PBMs contracting with group health plans.

HR 5973 and S 2323 - appropriations legislation covering the Food and Drug Administration

HR 5973 and S 2323 - appropriations legislation covering the Food and Drug Administration; S 3295 and similar draft House legislation - appropriations legislation covering the Agency for Healthcare Research and Quality

HR 5973/S 2323 - appropriations legislation covering the U.S. Food and Drug Administration; S 3295 and similar draft House legislation - appropriations legislation covering the Agency for Healthcare Research and Quality